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Empirical foundations for the diagnosis of
somatization: implications for DSM-5
J. G. M. Rosmalen*, L. M. Tak and P. de Jonge
Interdisciplinary Center for Psychiatric Epidemiology, University Medical Center Groningen, University of Groningen, Groningen,
The Netherlands
Background. The aim of this study was to develop empirically validated criteria for the diagnoses of clinically
relevant somatization.
Method. This study was performed in a population-representative cohort consisting of 461 males (47.8%) and 503
females (52.2%), with an average age of 55.8 years (S.D.=11.1). Somatization, anxiety and depression were derived
from the Composite International Diagnostic Interview. Mplus was used to perform conﬁrmative factor analyses on
the current DSM-IV symptom groups ; on alternative symptom clusters previously suggested ; and to perform latent
class analysis in order to deﬁne an empirically derived cut-oﬀ for somatization.
Results. The existence of symptom groups as described in DSM-IV was not supported by our data, whereas a
diﬀerentiation between cardiopulmonary, musculoskeletal, gastrointestinal and general somatic symptoms did ﬁt our
data. Latent class analysis revealed two classes characterized by few (n=859) and many (n=105) symptoms. The
class of subjects could be approached by a simple cut-oﬀ of four functional symptoms (sensitivity 79%, speciﬁcity
98%, positive predictive value 82%, negative predictive value 97%) regardless of the number of organ systems
involved.
Conclusions. This study in a large population-representative cohort suggests that a simple symptom count can be
used as a dimensional diagnosis of somatization. In those instances in which a categorical diagnosis is preferred, a
simple cut-oﬀ of four out of 43 functional symptoms best ﬁtted our data. We did not ﬁnd any added value for
incorporating the number of symptom clusters into the diagnostic criteria.
Received 3 May 2010 ; Revised 13 July 2010 ; Accepted 17 July 2010 ; First published online 16 September 2010
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Introduction
Functional symptoms are symptoms that cannot be
conclusively explained by organic pathology. Clusters
of functional symptoms are classiﬁed under somato-
form disorders in DSM-IV (APA, 1994). A classical
example of a disease characterized by various func-
tional somatic symptoms is somatization disorder. The
diagnostic criteria for somatization disorder described
in the diﬀerent DSM editions illustrate the diﬃculties
in constructing appropriate diagnostic criteria for
clinically relevant somatization. The original criteria
involved a lifetime history of 25 unexplained somatic
symptoms in addition to attitudinal features. DSM-III
criteria required a symptom count of 12 for males and
14 for females, which changed to 13 for both genders
in DSM-III-R. The current DSM-IV criteria require
eight symptoms originating from four designated
symptom groups. For the DSM-V, the diagnosis
of complex somatic symptom disorder is proposed
to replace the current diagnoses of somatization dis-
order, undiﬀerentiated somatoform disorder, hyp-
ochondriasis and pain disorder (Dimsdale & Creed,
2009). The proposed diagnostic criteria for complex
somatic symptom disorder require the presence
of somatic symptoms, together with misattributions,
excessive concern or preoccupation with symptoms
and illness and increased healthcare use.
The diagnostic criteria for somatization highlight
a number of issues that require empirical evaluation
in the general population. First, whereas the DSM-III
criteria required a simple symptom count, a DSM-IV
diagnosis of somatization disorder requires a combi-
nation of symptoms from several symptom groups : at
least four pain symptoms, two gastrointestinal, one
sexual and one pseudoneurological. This criterion
implies a clustering of symptoms in the diﬀerent de-
signated symptom groups. Some studies, especially
those performed in primary care or community
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settings, have indeed suggested that certain types of
symptoms tend to cluster (Swartz et al. 1986 ; Simon
et al. 1996 ; Liu et al. 1997 ; Robbins et al. 1997 ; Gara et al.
1998 ; Kroenke et al. 1998; Fink et al. 2007). However,
the latent factors observed in these studies do not
completely resemble the DSM-IV symptom groups.
Commonly identiﬁed factors are gastrointestinal,
musculoskeletal, neurological/conversion and cardio-
pulmonary/autonomic (Swartz et al. 1986 ; Simon et al.
1996 ; Robbins et al. 1997 ; Gara et al. 1998; Kroenke
et al. 1998 ; Fink et al. 2007), although not all studies
replicated the existence of all four factors. The indi-
vidual factors were highly correlated in several of
these studies, suggesting that a more general higher
order somatization factor explained the majority of
the variance in functional symptoms (Liu et al. 1997 ;
Deary, 1999 ; Fink et al. 2007). Clinically meaningful
symptom clusters could not be identiﬁed mainly in
studies performed in specialist care settings (Hiller
et al. 2001 ; Nimnuan et al. 2001b ; Sullivan et al. 2002).
It therefore remains unknown whether symptom
clusters exist, as is implicitly assumed in DSM-IV,
or whether an underlying somatization factor is re-
sponsible for symptoms in general, as is assumed in
DSM-III and the DSM-5 proposal.
Second, it is unclear whether an appropriate symp-
tom count threshold for somatization can be set. In
contrast to the categorical approach of previous DSM
editions, the proposed diagnosis of complex somatic
symptom disorders in DSM-5 is based on a dimen-
sional approach (Dimsdale & Creed, 2009). Support
for such an approach comes from the linear relation-
ship between the number of somatic symptoms and
several indicators of construct validity, including
functional impairment, childhood and family risk
factors, psychiatric co-morbidity and healthcare use
(Kroenke et al. 2007). In addition to a dimensional
diagnosis, it may be useful to deﬁne a categorical ap-
proach for clinically relevant somatization, both from
a clinical and a research point of view. In that case, it is
important to empirically justify a cut-oﬀ score.
Third, it is unclear whether the diagnostic criteria
should include a threshold for the number of organ
systems involved. DSM-IV criteria for somatization
disorder included a requirement for symptoms orig-
inating from four organ systems, whereas this re-
quirement is not included in the proposed diagnosis
of complex somatic symptom disorders in DSM-5
(Dimsdale & Creed, 2009). It has never been formally
tested whether or not this threshold is required or
which minimum number of organ systems would be
appropriate.
The aim of this study was to empirically evaluate
criteria for the diagnosis of clinically relevant somati-
zation. We formulated the following questions. First,
are there indications for symptom clusters within the
functional symptoms, such as deﬁned in the current
DSM-IV classiﬁcation or in some of the alternative
proposals? Second, is it possible to deﬁne a cut-oﬀ for
clinically relevant somatization based on population-
based empirical data? Third, is there an empirically
supported minimum number of organ systems re-
quired?
We performed our study in a population cohort
using data on somatization derived from the
Composite International Diagnostic Interview (CIDI).
In accordance with the DSM-5 proposal, we per-
formed our analyses on recent symptoms instead of
lifetime symptoms, because detailed inquiry about
lifetime symptoms is typically not feasible in busy
clinical settings and lifetime recall of functional
symptoms is highly inconsistent (Kroenke et al. 1997 ;
Simon & Gureje, 1999).
Methods
Population
Our study has been performed in a cohort derived
from Prevention of Renal and Vascular End Stage
Disease (PREVEND), a population cohort study in-
vestigating micro-albuminuria as a risk factor for renal
and cardiovascular disease. The recruitment of par-
ticipants has been extensively described elsewhere
(Pinto-Sietsma et al. 2000). All inhabitants of the city
of Groningen between the ages of 28 and 75 years
(85 421 subjects) were asked to send in a morning
urine sample and to ﬁll out a short questionnaire on
demographics and cardiovascular history. A total of
40 856 subjects (47.8%) responded. After exclusion of
subjects with insulin-dependent diabetes mellitus and
pregnant women, all subjects with an elevated urinary
albumin concentration of o10 mg/l (n=7768), to-
gether with a randomly selected control group with
a urinary albumin concentration of <10 mg/l (n=
3395), were invited for further investigations (total
n=11 163). Finally, 8592 subjects completed the total
screening programme, making up the PREVEND
study cohort. Because the PREVEND study popu-
lation was enriched for albuminuria, this over-
sampling for albuminuria was counterbalanced in
the current substudy. Albuminuria-negative partici-
pants and a random sample of albuminuria-positive
participants were combined so that a population-
representative ratio of albuminuria-positive partici-
pants was achieved.
Research assistants handed over invitations in
the 2001–2002 wave to 2554 subjects to participate
in a substudy, for which additional psychiatric
and psychosocial data were collected. Of these 2554
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subjects, 1094 (43%) completed the additional meas-
urements. Follow-up measurements in the 2003–2004
wave were completed by a total of 976 participants
(89% of the cohort with additional psychiatric and
psychosocial data), forming the cohort for the current
study. The study was approved by the local medical
ethics committee and all subjects gave written in-
formed consent to participate.
Somatization
Somatization was measured by the somatization
section of the CIDI. A fully computerized version of
the CIDI 2.1 12-month version was applied, suitable
for self-administration. Trained interviewers were
present for questions and for participants who needed
computer help. The probing scheme of the self-
administered version is completely identical to the
interviewer-administered version; the diﬀerence be-
tween both versions is that the questions are not read
out loud by the interviewer but instead are read on
the screen by the participant him/herself. In short, the
CIDI somatization section surveys the occurrence of
43 symptoms in the past year. Symptoms are con-
sidered present when they meet severity criteria, i.e.
provoke a healthcare visit. If these criteria are met, the
interview assesses in a hierarchical fashion whether
a medical doctor diagnosed a symptom as due to
physical illness or injury, or whether a symptom was
caused by the use of medication, drugs or alcohol.
If these inquiries are negative for these medical ex-
planations, the symptom is scored as a functional
symptom. As an additional validation step, we
checked all medical diagnoses that participants in-
dicated in the case of medically explained symptoms.
In those cases in which the diagnosis involved a
functional syndrome (such as irritable bowel syn-
drome, chronic fatigue syndrome or ﬁbromyalgia), we
recoded the symptom as a functional symptom. The
CIDI has adequate test–retest reliability and validity
(Andrews & Peters, 1998). Complete CIDI data were
available for 964 participants (99% of the current
study cohort).
Conﬁrmatory factor analyses to test the presence
of symptom clusters (question 1)
In order to test previously postulated symptom
clusters, we performed conﬁrmatory factor analyses
for binary data using Mplus 3.11 (Muthen & Muthen,
2004). We ﬁrst tested the symptom clusters currently
deﬁned in the CIDI DSM-IV scoring algorithm: pain
symptoms; gastrointestinal symptoms other than
pain ; sexual or reproductive symptoms other than
pain ; pseudoneurological symptoms (see Table 1 for
included symptoms). Because of the diﬀerent deﬁ-
nition of the sexual symptom cluster in the CIDI scor-
ings syntax rules, we performed these analyses
separately for males and females. Urinary retention
and diﬃculty swallowing or lump in throat were not
reported by males and thus not included in the
analyses in males. Symptoms that are combined in
the CIDI scorings algorithm were included as separate
symptoms in these analyses.
In addition, we performed a conﬁrmatory factor
analysis using cardiopulmonary, musculoskeletal and
gastrointestinal factors resembling those previously
reported by Kroenke et al. (1998) and Fink et al. (2007).
We also tested a four-factor model, including the
factor general symptoms (see Table 1 for included
symptoms). Finally, we performed a conﬁrmatory
factor analysis including a second order factor re-
presenting a common latent factor underlying the
cardiopulmonary, musculoskeletal and gastrointesti-
nal symptom groups. The models were deemed to ﬁt
the data well if all of the following goodness-of-ﬁt in-
dices were satisﬁed: overall x2 goodness-of-ﬁt test
non-signiﬁcant ; Comparative Fit Index (CFI)>0.95 ;
root mean square error of approximation (RMSEA)
f0.05 (Hu & Bentler, 1999).
Latent class analyses to identify an empirically
based cut-oﬀ (question 2)
In order to establish an empirically derived threshold
for somatization, we applied latent class analysis
(LCA) to the CIDI symptoms, using Mplus 3.11
(Muthen & Muthen, 2004). LCA is a statistical model-
ﬁtting method identifying diﬀerent subgroups
(classes) of participants within a given dataset, in this
study characterized by similar symptom proﬁles. LCA
uses statistical criteria to identify and accurately enu-
merate the groups that best ﬁt the data. Instead of
giving a particular true solution, LCA produces solu-
tions for diﬀerent numbers of classes with relative ﬁt
indices. The Bayesian information criterion (BIC) was
used for the goodness-of-ﬁt to determine the optimal
number of classes. The BIC is a parsimony index de-
termining how improvements in goodness-of-ﬁt are
counterbalanced by increased complexity due to the
greater number of parameters. The null model is for
one single class, i.e. the whole cohort belonging to the
same latent class. This model is rejected when models
with two or more parameters result in smaller BIC
values. The best model ﬁt is thus indicated by the
smallest BIC value. For any given latent class model,
each participant has an estimated probability of being
a member of each latent class and participants were
allocated to the latent classes of which they were
most likely to be a member. We performed separate
Empirical foundations for the diagnosis of somatization 1135
LCAs for the entire cohort and for males or females
separately, either including the 29 CIDI symptoms
eliciting a positive response fromo10 participants or
including 23 CIDI symptoms after excluding the six
reproductive and sexual symptoms (see Table 1 for
included symptoms). In line with previous reports
(Fink et al. 2007), we decided a priori to include
only those items that were present in at least 10 re-
spondents, since including items with a low preva-
lence increases the risk of identifying non-replicable
Table 1. Included symptoms in the various conﬁrmatory factor analyses and latent class analyses
DP DGI DSR DPN CP MS GI GS LCA29 LCA23
Abdominal pain * * * *
Back pain * * * *
Joint pain * * * *
Pain in extremities * * * *
Chest pain * * * *
Headache * * * *
Pain during menstruation * *
Pain during urination *
Urinary retention *
Burning sensation genitals * *
Pain additional sites * * *
Vomiting other than during pregnancy *
Vomiting throughout pregnancy * * *
Nausea * * * *
Diarrhoea * * * *
Feeling bloated or full of gas * * * *
Intolerance of several foods * * * *
Blindness *
Blurred vision * *
Deafness *
Impaired balance * * * *
Impaired coordination * *
Loss of touch or pain sensation * * * *
Paralysis *
Aphonia * * *
Seizures *
Dizziness * * *
Loss of consciousness other than fainting *
Dissociative symptoms such as amnesia *
Double vision * * *
Shortness of breath * * *
Localized weakness * * * *
Skin blotches or discoloration * *
Bad taste in mouth, excessively coated tongue
Frequent urination * *
Numbness – tingling * * *
Diﬃculty swallowing or lump in throat * * *
Irregular menses *
Excessive menstrual bleeding * *
Sexual indiﬀerence * *
Pain during sexual intercourse *
Unpleasant sexual intercourse * *
Other sexual problems * *
The ﬁrst four columns include DSM factors that compose the diagnostic criteria for DSM-IV somatization disorder :
DP, DSM Pain ; DGI, DSM gastrointestinal other than pain ; DSR, DSM sexual/reproductive other than pain ; DPN, DSM
pseudoneurological. The second four columns include previously suggested symptom clusters : CP, cardiopulmonary factor ;
MS, musculoskeletal factor ; GI, gastrointestinal factor ; GS, general symptoms factor. The last two columns summarize which
symptoms were included in the latent class analyses with (LCA29) and without (LCA23) the reproductive symptoms.
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latent classes. To index the amount to which
symptoms discriminated the latent classes, we used
Cramer’s V, which is a correlation coeﬃcient based on
the x2 statistic. Accordingly, Cramer’s V2 is similar to
R2 in regression models and, in this case, reﬂects how
much of the variability in the dependent variable is
explained by latent class membership.
Descriptive analyses and the calculation of sensi-
tivity, speciﬁcity and predictive values of various
symptom thresholds for latent class membership were
analysed using SPSS 16.0 (SPSS Inc., USA). Two-sided
p values<0.05 were considered signiﬁcant.
Results
General characteristics
The current study cohort consists of 461 males (47.8%)
and 503 females (52.2%), with an average age of 55.8
years (S.D.=11.1, minimum 35.9 years, maximum 82.3
years). A total of 583 participants reported at least one
functional symptom, while the maximum number of
reported functional symptoms was 18. A statistically
signiﬁcant gender diﬀerence was found in the total
number of symptoms reported [median (IQ range)
males 1 (0–1) v. females 1 (0–2), Z=x6.919, p<0.001].
Since this gender diﬀerence might be related to the fact
that the CIDI interview includes reproductive and
sexual symptoms that are not equally applicable to
men and women, we repeated the analysis excluding
these symptoms and found that the gender diﬀerence
remained [median (IQ range) males 1 (0–1) v. females 1
(0–2), Z=x5.559, p<0.001]. In addition to female re-
productive symptoms, signiﬁcant gender diﬀerences
existed for a variety of pain symptoms (back, joints,
extremities, head, additional sites), dizziness, intoler-
ance of several foods, bad taste in mouth, or excess-
ively coated tongue, diﬃculty swallowing or lump
in throat, sexual indiﬀerence and unpleasant sexual
intercourse, with women scoring higher for all these
symptoms. There was no association between the total
number of functional symptoms and age (Spearman’s
rho=0.037, p=0.256).
Question 1: Symptom clusters
We ﬁrst performed a conﬁrmatory factor analysis on
the symptom groups that form the core of the current
DSM-IV diagnostic criteria for somatization disorder.
We used the CIDI scoring rules to deﬁne groups of
pain symptoms, gastrointestinal symptoms other than
pain, sexual or reproductive symptoms other than
pain and pseudoneurological symptoms (included
symptoms are described in Table 1). Because of the
diﬀerent deﬁnition of the sexual or reproductive
symptom cluster, we performed these analyses
separately for males and females. We did not ﬁnd
a satisfactory ﬁt, for males [x2(degrees of freedom
(df=15)=28.077, p=0.0211 ; CFI=0.874; RMSEA=
0.043] nor for females [x2(df=32)=64.553, p=0.0006;
CFI=0.843 ; RMSEA=0.045]. Although, in both cases,
RMSEA was<0.05, CFI was not>0.95 and the x2 test
was signiﬁcant.
In addition, we performed a conﬁrmatory factor
analysis using factors resembling those previously re-
ported (Kroenke et al. 1998 ; Fink et al. 2007). Since
these factors were deﬁned based on datasets including
both males and females, we also tested them on the
entire cohort. We deﬁned a cardiopulmonary factor, a
musculoskeletal factor and a gastrointestinal factor
(included symptoms are described in Table 1). The ﬁt
of this model was relatively good [x2(df=31)=45.067,
p=0.0492 ; CFI=0.957 ; RMSEA=0.022] and this three-
factor model ﬁtted our data signiﬁcantly better than
the corresponding one-factor model [x2 for diﬀerence
testing (df=3)=28.324, p<0.0001]. We also tested a
four-factor model, including a general symptoms fac-
tor as suggested previously (Fink et al. 2007). This
model had a good ﬁt to the data [x2(df=29)=40.073,
p=0.0828 ; CFI=0.963 ; RMSEA=0.020] and again
model ﬁt was signiﬁcantly better than that of the cor-
responding one-factor model [x2 for diﬀerence testing
(df=6)=29.748, p<0.0001]. Finally, we performed a
conﬁrmatory factor analysis including a second order
factor representing a common latent factor underlying
the cardiopulmonary, gastrointestinal and muscu-
loskeletal symptom groups suggested previously
(Fink et al. 2007). Also, this model had a relatively
good ﬁt to the data [x2(df=31)=45.067, p=0.0492;
CFI=0.957 ; RMSEA=0.022].
Question 2: Empirically-based cut-oﬀ
LCA was performed in order to identify diﬀerent
classes of subjects within our dataset and to test whe-
ther subjects were classiﬁed according to symptom
proﬁle or to symptom count. We performed separate
LCAs including either 29 or 23 symptoms (in the latter
case excluding the reproductive and sexual symp-
toms) and for the entire cohort or males and females
separately. Table 2 shows the BIC values of the LCA
solutions of the diﬀerent models. The best model ﬁt
(indicated by the smallest BIC value) in all analyses
was achieved with a two-class model.
We continued with analyses on the total cohort in-
cluding the 23 symptoms that were not gender speciﬁc
(results for 29 symptoms are comparable and available
upon request). Table 3 shows the proportion (and
number) of participants in latent classes 1 and 2 re-
porting a particular symptom. For all symptoms, the
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proportion of subjects with a positive response was
higher for class 1 members than for class 2 members.
There were no speciﬁc symptoms characterizing class
membership ; participants in one of the classes dis-
played few symptoms (n=859) and participants in the
other class (n=105) presented many symptoms.
We next tested whether we could approach the LCA
analysis results with a simple cut-oﬀ score solely
based on the total number of symptoms. We included
all symptoms in this cut-oﬀ to test whether our LCA
classes could also be approached by a cut-oﬀ score that
was not restricted to the symptoms included in the
Table 2. Goodness-of-ﬁt for the latent class analyses solutions
BIC value
Symptoms with at least 10 positive
responses in the total cohort*
Symptoms with at least 10 positive responses in the total
cohort, excluding six reproductive and sexual symptoms
Class solution Total cohort Females Males Total cohort Females Males
1-class 9851.229 6010.069 3819.341 8150.172 4959.507 3204.632
2-class 9439.473 5822.640 3752.171 7754.167 4757.430 3155.542
3-class 9526.361 5916.439 3859.751 7817.547 4820.862 3253.088
4-class 9683.176 6037.085 3982.936 7908.795 4904.980 3358.085
BIC, Bayesian information criterion (values represent not sample-size adjusted BIC values).
* In males excluding pain during menstruation and excessive menstrual bleeding.
Table 3. Distribution of symptoms in latent classes based on latent class analysis applied to symptoms with at least 10 positive responses
in the total cohort, excluding reproductive and sexual symptoms
Proportion (number) reporting symptom
Cramer’s V p
Latent class 1 Latent class 2
(n=105) (n=859)
Abdominal pain 0.43 (45) 0.04 (34) 0.442 <0.001
Diﬃculty swallowing or lump in throat 0.29 (30) 0.02 (16) 0.390 <0.001
Feeling bloated or full of gas 0.28 (29) 0.02 (16) 0.380 <0.001
Pain in extremities 0.42 (44) 0.06 (55) 0.364 <0.001
Localized weakness 0.17 (18) 0 (3) 0.356 <0.001
Loss of touch or pain sensation 0.23 (24) 0.01 (12) 0.353 <0.001
Joint pain 0.45 (47) 0.08 (71) 0.347 <0.001
Headache 0.4 (42) 0.07 (60) 0.334 <0.001
Back pain 0.39 (41) 0.07 (62) 0.321 <0.001
Intolerance of several foods 0.16 (17) 0.01 (6) 0.316 <0.001
Dizziness 0.3 (32) 0.04 (38) 0.313 <0.001
Impaired balance 0.18 (19) 0.01 (10) 0.309 <0.001
Chest pain 0.22 (23) 0.03 (25) 0.272 <0.001
Nausea 0.1 (10) 0 (3) 0.248 <0.001
Pain additional sites 0.17 (18) 0.02 (19) 0.242 <0.001
Numbness/tingling 0.14 (15) 0.02 (13) 0.237 <0.001
Shortness of breath 0.13 (14) 0.01 (11) 0.236 <0.001
Blurred vision 0.12 (13) 0.02 (15) 0.197 <0.001
Double vision 0.07 (7) 0.01 (6) 0.161 <0.001
Diarrhoea 0.08 (8) 0.01 (11) 0.142 <0.001
Frequent urination 0.08 (8) 0.02 (19) 0.102 0.002
Aphonia 0.07 (7) 0.02 (17) 0.094 0.004
Skin blotches or discoloration 0.06 (6) 0.02 (14) 0.089 0.006
Symptoms are sorted by Cramer’s V ; higher values of Cramer’s V indicate symptoms that better discriminated the latent
classes.
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input dataset on which the deﬁnition of the classes
was based. Fig. 1 depicts the proportion of participants
in the diﬀerent latent classes in relation to functional
symptom count. Based on this ﬁgure, we tested sensi-
tivity, speciﬁcity, positive predictive value (PPV) and
negative predictive value (NPV) of cut-oﬀ three, four
and ﬁve symptoms to determine class membership,
including all 43 symptoms to determine whether par-
ticipants scored above or below the cut-oﬀ. A cut-oﬀ
of three has a high sensitivity and speciﬁcity (1.00
and 0.92, respectively), but the PPV is low (0.59 ;
NPV=1.00). A cut-oﬀ of ﬁve, on the other hand, has a
good PPV and NPV (0.92 and 0.95, respectively), but
is not very sensitive (sensitivity 0.56, speciﬁcity 0.99).
A threshold of four symptoms is the optimal cut-oﬀ
in terms of sensitivity and predictive value. A simple
cut-oﬀ score of four out of 43 symptoms correctly
identiﬁed 79% of the LCA class 1 participants (and
98% of the LCA class 2 participants) while correctly
classifying 97% of participants scoring below and 82%
of participants scoring about the cut-oﬀ as LCA classes
2 and 1, respectively. When we based our cut-oﬀ score
on the 23 prevalent symptoms, not on all symptoms,
the optimal cut-oﬀ in terms of sensitivity (1.00),
speciﬁcity (0.97), PPV (0.82) and NPV (1.00) was three
symptoms.
Question 3: The multiple organ system requirement
We tested the number of symptom clusters involved
in participants scoring above and below the cut-oﬀ of
four symptoms, using the cardiopulmonary, gastroin-
testinal, musculoskeletal and general symptom clus-
ters that were found to ﬁt our empirical data. Of
participants scoring above the cut-oﬀ, in 10.9% only
one symptom cluster was involved, whereas in 47.5%
two symptom clusters were involved, in 32.7% three
and in 8.9% all four clusters were involved.
Table 4 summarizes the co-morbidity with DSM-IV
common mental disorders. High co-morbidity is
found, since participants scoring above the cut-oﬀ of
four symptoms have a more than four times higher
risk of having any anxiety and depression disorder
than participants scoring below the cut-oﬀ. All speciﬁc
diagnoses more often occur in participants scoring
above the cut-oﬀ; with one remarkable exception, the
simple phobia of the blood- or injection-injury type is
absent in somatizers but not in controls (0.0 v. 0.5%),
whereas all other speciﬁc phobias are more prevalent
in the somatizers than in the controls (animal type 2.0
v. 0.1, natural environment type 2.0 v. 0.8, situational
type 2.0 v. 1.0). When comparing the number of in-
volved symptom clusters, the increased co-morbidity
with depression and anxiety is evident from one
symptom cluster onwards, reaching its maximum at
two symptom clusters.
Discussion
This study in a large population-representative cohort
suggests that a simple symptom count can be used as a
dimensional diagnosis of somatization, as suggested
in the DSM-5 proposal. In those instances in which
a categorical diagnosis is preferred, a simple cut-oﬀ
of four out of 43 functional symptoms best ﬁtted
our data. We did not ﬁnd any added value for in-
corporating the number of symptom clusters into the
diagnostic criteria.
A major strength of our study is the use of a popu-
lation sample including approximately equal numbers
of both genders covering a wide age range. Moreover,
we performed structured psychiatric interviews in all
participants ; thus, not selecting subjects on the basis
of a screening questionnaire. In addition, we focused
on recent symptoms, whereas past epidemiological
studies of somatization relied on lifetime symptoms.
There are also a few limitations to discuss. First, we
used self-reported presence of functional symptoms,
possibly underestimating the real prevalence if people
tend to seek a physical reason for their complaints.
There is no consensus about whether symptoms as-
cribed to functional syndromes should be classiﬁed
as somatization symptoms. The classiﬁcation of these
symptoms as either somatization symptoms or medi-
cally explained symptoms did not essentially inﬂu-
ence the current results. Second, the utility of both
factor analyses and LCA is critically dependent on
the input dataset. The fact that pseudoneurological
symptoms do not cluster with one of the large clusters
such as gastrointestinal or cardiovascular symptoms
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Fig. 1. Proportion of participants in latent class 1 (––) and
class 2 (– – –) in relation to functional symptom count. Latent
class 1 is characterized by high numbers of functional
symptoms, whereas latent class 2 is characterized by low
numbers of functional symptoms.
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despite the fact that we used the CIDI interview, we
were able to conﬁrm previously suggested symptom
clusters that were deﬁned using the SCAN interview
(Fink et al. 2007) and using a 15-symptom checklist
derived from the PRIME-MD (Kroenke et al. 1998).
Third, only 43% of approached people agreed to par-
ticipate. Previous analyses indicated no diﬀerences in
gender, age or neuroticism between those who parti-
cipated and those who refused (Tak et al. 2010), mak-
ing it unlikely that selection bias essentially inﬂuenced
our results.
Our data fail to provide empirical support for the
designated symptom clusters in the DSM-IV. It is
important to note that we performed our analysis on
symptoms experienced in the previous 12 months,
whereas the DSM-IV diagnostic criteria refer to life-
time symptoms. We present the ﬁrst study, which
formally tested the DSM-IV symptom groups using
conﬁrmatory factor analyses. Our results are in
agreement with exploratory analyses that also did not
replicate the DSM-IV clusters in a general population
cohort (Liu et al. 1997). When using previously sug-
gested symptom clusters that did ﬁt our data, almost
90% of participants scoring above our cut-oﬀ have
symptoms derived from more than one symptom
cluster, suggesting that there is little additional value
for a minimum required number of organ systems.
Similarly, data on psychiatric co-morbidity also do not
give indications for such a multiple organ system
threshold. Clinically signiﬁcant somatization is known
to be accompanied by psychiatric co-morbidity
(de Waal et al. 2004 ; Haug et al. 2004). An abrupt in-
crease in psychiatric co-morbidity beyond a certain
threshold number of involved symptom clusters could
thus be regarded as indicative of a dichotomy between
states of health (innocent symptoms) and disease
(clinically relevant somatization). Our data do not
support such a symptom cluster threshold. Despite the
fact that previously suggested clusters ﬁt our data,
LCA revealed that participants are clustered based on
symptom count instead of symptom proﬁle. This is
in agreement with several earlier studies that found
highly correlated symptom factors, suggesting that a
general higher order somatization factor explained the
majority of the variance in functional symptoms (Liu
et al. 1997 ; Deary, 1999 ; Fink et al. 2007).
Our data underline the validity of a dimensional
approach of diagnosing. Nonetheless, if a categorical
approach is preferred, our data indicate that a simple
cut-oﬀ of four symptoms best distinguishes somatizers
from non-somatizers. Although the mere counting of
physical complaints as a basis for the classiﬁcation has
been criticized in the past (Fink, 1996), it has been
shown that the number of bodily symptoms is still an
important feature for the prediction of course and
outcome (Jackson et al. 2006; Kroenke et al. 2007). Our
results seem in agreement with results on multi-
somatoform disorder (MSD), which is deﬁned as three
or more currently bothersome unexplained physical
complaints (from a 15-symptom checklist), plus a his-
tory of chronic somatization (i.e. unexplained symp-
toms that were usually present for at least 2 years)
(Kroenke et al. 1997). In fact, when we based our cut-
oﬀ score on the 23 prevalent symptoms, not on all
symptoms, which might be more practical in clinical
situations, the appropriate cut-oﬀ would be three
symptoms. Despite diﬀerences in the number of
symptoms and the time-frame, there are remarkable
similarities between our cut-oﬀ and MSD. It is inter-
esting that MSD was present in 8% (Spitzer et al.
1994 ; Jackson & Kroenke, 2008) to 19% (Dickinson
et al. 2003) of primary care patients, compared with a

















Any depression or anxiety disorder 11.8 8.8 37.6 27.3 37.5 39.4 44.4
Major depression 7.0 5.1 22.8 27.3 22.9 21.2 22.2
Dysthymia 0.4 0 4.0 0 2.1 6.1 11.1
Generalized anxiety disorder 2.7 1.9 9.9 18.2 8.3 9.1 11.1
Panic disorder 0.9 0.6 4.0 0 0 9.1 11.1
Agoraphobia without history
of panic disorder
0.5 0.3 2.0 0 2.1 0 11.1
Agoraphobia with or without
history of panic disorder
0.8 0.5 4.0 0 2.1 3.0 22.2
Social phobia 1.5 0.9 5.9 0 6.2 9.1 0
Simple phobia 2.3 2.0 5.0 0 4.2 6.1 11.1
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comparable proportion of 11% scoring above our cut-
oﬀ in our population cohort. In addition, psychiatric
co-morbidity is strikingly similar. Major depression
was present in 21% of patients with MSD and 23%
of patients above our cut-oﬀ, generalized anxiety dis-
order was present in 11% with MSD and 10% of our
somatizers and panic disorder was present in 2% with
MSD and 4% of patients above our cut-oﬀ (Jackson &
Kroenke, 2008). It appears that our LCA-based cut-oﬀ
might identify the patients who fulﬁl the diagnostic
criteria for MSD. Unfortunately, not all MSD symp-
toms are surveyed in the CIDI and it is thus not poss-
ible to calculate the agreement.
Further research should validate these results in
other populations and using other interviews. Given
the fact that, in some specialties, functional symptoms
outnumber the medically explained symptoms
(Nimnuan et al. 2001a), the importance of these vali-
dations is not restricted to psychiatric settings. The
observation that the majority of participants included
in the subgroup with high levels of functional symp-
toms do not show a depression or anxiety disorder
underlines the broader importance of these ﬁndings.
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